eligibility_summary
Adults 18–70 with TP53‑mutated DLBCL, measurable disease (Lugano 2014), ECOG 0–2, ≥3‑month survival, adequate marrow/liver/kidney, and consent. Exclude: other/transformed lymphoma, CNS disease, prior XPO1 inhibitor, drug contraindications, active HBV/HCV or HIV (HBV/HCV allowed if low/undetectable viral load, HBV prophylaxis needed), GI malabsorption, pregnancy/lactation or no contraception, inability to consent, or investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: single-arm phase II testing selinexor plus R-CHOP first-line in TP53-mutated DLBCL, with selinexor maintenance after CR. Drugs/mechanisms (type): • Selinexor (oral small-molecule SINE/XPO1 inhibitor): blocks nuclear export (exportin-1), retains tumor suppressors (p53 family, RB, FOXO) in nucleus, dampens NF-κB, induces apoptosis. • Rituximab (anti-CD20 monoclonal antibody): B-cell depletion via ADCC/CDC/apoptosis. • Cyclophosphamide (alkylating agent): DNA crosslinking. • Doxorubicin (anthracycline): topoisomerase II inhibition/free radical DNA damage. • Vincristine (vinca alkaloid): microtubule inhibition. • Prednisone (corticosteroid): glucocorticoid receptor–mediated lymphocyte apoptosis. Cells/pathways targeted: CD20+ malignant B cells, XPO1 nuclear export, DNA damage/repair, topoisomerase II, mitotic spindle, glucocorticoid apoptotic signaling, immune-mediated cytotoxicity.